KRK Krka, d. d.

277.44USD1116.00 PLN · GPW+0.54%Mkt Cap: 8.40B USDP/E: 19.08

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Centr…

Institutional holders7 on file

Key Statistics

Company
Market Cap8.40B USD
Enterprise Value8.25B USD
Revenue (TTM)2.38B USD
Gross Profit1.30B USD
Net Income (TTM)442.27M USD
Revenue/Share78.41 USD
Last Price277.44 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees13.3K
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSI0031102120
Valuation
P/E (Trailing)19.08
P/E (Forward)—
PEG—
EV/EBITDA51.63
EV/Revenue3.47
P/S15.59
P/B13.99
EPS (TTM)64.14 USD
EPS (Forward)—
52W Range
201.3778% of range298.33
52W High298.33 USD
52W Low201.37 USD
Profitability
Gross Margin57.96%
Oper. Margin25.45%
EBITDA Margin29.67%
Profit Margin19.76%
ROE17.10%
ROA13.25%
ROIC22.21%
ROCE18.33%
Growth
Revenue Growth11.40%
Earnings Growth36.10%
Cash Flow & Leverage
Operating CF579.79M USD
CapEx (TTM)107.87M USD
FCF Margin10.26%
FCF Yield2.90%
Net Debt-618.59M USD
Net Debt/EBITDA-0.88
Net Debt/FCF-2.54
Balance Sheet
Debt/Equity0.01
Current Ratio4.05
Quick Ratio2.60
Book Value/Sh87.50 USD
Cash/Share21.13 USD
Dividends
Fwd Div Rate9.80 USD
Trail. Div Rate2.26 USD
Div. Yield3.55%
5Y Avg Yield4.68%
Payout Ratio59.96%
Ex-Div DateJul 21, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.30.28M
Float20.96M
Insiders16.33%
Institutions12.72%
Technical
SMA 50278.27 (-0.3%)
SMA 200269.49 (+3.0%)
Beta0.45
S&P 52W Chg12.00%
Avg Vol (30d)75
Avg Vol (10d)83
Technical Indicators
RSI (14)52.9
MACD-2.9945
MACD Signal-6.0679
MACD Hist.+3.0734
BB Upper282.81 USD
BB Middle274.88 USD
BB Lower266.95 USD
BB Width5.77%
ATR (14)4.250 USD
Vol Ratio (20d)5.25x

About Krka, d. d. (WSE: KRK)

›

Krka, d. d. (WSE: KRK) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 13,307 employees.

The shares were at 1116.00 PLN on 19 November 2026, up 25.4% over 52 weeks. Its 52-week range is 810.00 PLN to 1200.00 PLN: the price is 7.0% below the high and 37.8% above the low.

At a market capitalisation of 33.79B PLN, it trades at 19.1 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 27% for KRK. It pays a dividend yielding 3.55% (it pays out 60% of its earnings), against a median of 1.88% among the dividend payers in that peer group.

Krka, d. d. reports return on equity of 17.1%, an operating margin of 25.4% and revenue up 11.4% year over year.

It holds more cash than debt, a net cash position of 563.99M EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. The next earnings report is expected on 11 March 2027.